首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation
【24h】

Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation

机译:新型喹诺酮类有效和选择性HDAC6抑制剂:合成,分子建模研究和生物学调查

获取原文
获取原文并翻译 | 示例
           

摘要

In this work we describe the synthesis of potent and selective quinolone-based histone deacetylase 6 (HDAC6) inhibitors. The quinolone moiety has been exploited as an innovative bioactive cap-group for HDAC6 inhibition; its synthesis was achieved by applying a multicomponent reaction. The optimization of potency and selectivity of these products was performed by employing computational studies which led to the discovery of the diethylaminomethyl derivatives 7g and 7k as the most promising hit molecules. These compounds were investigated in cellular studies to evaluate their anticancer effect against colon (HCT-116) and histiocytic lymphoma (U9347) cancer cells, showing good to excellent potency, leading to tumor cell death by apoptosis induction. The small molecules 7a, 7g and 7k were able to strongly inhibit the cytoplasmic and slightly the nuclear HDAC enzymes, increasing the acetylation of tubulin and of the lysine 9 and 14 of histone 3, respectively. Compound 7g was also able to increase Hsp90 acetylation levels in HCT-116 cells, thus further supporting its HDAC6 inhibitory profile. Cytotoxicity and mutagenicity assays of these molecules showed a safe profile; moreover, the HPLC analysis of compound 7k revealed good solubility and stability profile. (C) 2020 Published by Elsevier Masson SAS.
机译:在这项工作中,我们描述了基于喹诺酮类药物的有效和选择性组蛋白去乙酰化酶6(HDAC6)抑制剂的合成。喹诺酮类化合物已被开发为一种创新的生物活性帽基,用于抑制HDAC6;它的合成是通过应用多组分反应实现的。通过计算机研究对这些产物的效力和选择性进行优化,从而发现二乙氨基甲基衍生物7g和7k是最有希望的hit分子。在细胞研究中对这些化合物进行了研究,以评估它们对结肠癌(HCT-116)和组织细胞淋巴瘤(U9347)癌细胞的抗癌作用,显示出良好至极好的效力,通过诱导凋亡导致肿瘤细胞死亡。小分子7a、7g和7k能够强烈抑制细胞质和少量的核HDAC酶,分别增加微管蛋白和组蛋白3的赖氨酸9和14的乙酰化。化合物7g还能够增加HCT-116细胞中的Hsp90乙酰化水平,从而进一步支持其HDAC6抑制特性。这些分子的细胞毒性和致突变性试验显示其安全性;此外,化合物7k的HPLC分析显示出良好的溶解性和稳定性。(C) 2020年由爱思唯尔马森SAS出版。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号